Literature DB >> 3498606

Pneumocystis carinii pneumonia therapy with 9-deazainosine in rats.

J W Smith1, M S Bartlett, S F Queener, M M Durkin, M A Jay, M T Hull, R S Klein, J J Marr.   

Abstract

An inosine analog, 9-deazainosine, has previously been demonstrated to inhibit Pneumocystis carinii in culture with WI-38 cells. The present study shows that it is also effective against Pneumocystis carinii in immunosuppressed Sprague-Dawley rats with Pneumocystis carinii pneumonia. After 8 wk of immunosuppression, rats that developed severe Pneumocystis carinii pneumonia were treated with either 9-deazainosine or served as controls. After 15 days of therapy, animals were sacrificed and severity of infection determined by morphologic examination of lungs for numbers of Pneumocystis carinii. Treated animals had greatly reduced numbers of Pneumocystis carinii trophozoites and cysts, compared with controls. This drug shows promise for therapy of Pneumocystis carinii pneumonia and should be studied further.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498606     DOI: 10.1016/0732-8893(87)90028-9

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  10 in total

1.  Opportunistic infections in HIV-infected patients.

Authors:  S D Shafran
Journal:  Can J Infect Dis       Date:  1992-03

2.  Models for evaluating compounds for activity against Pneumocystis carinii.

Authors:  M S Bartlett
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

3.  Furazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J Foy; J L Zhang
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  Guanylhydrazones in therapy of Pneumocystis carinii pneumonia in immunosuppressed rats.

Authors:  P D Walzer; J Foy; J Runck; P Steele; M White; R S Klein; B A Otter; R J Sundberg
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

5.  Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; J D Richardson; M M Durkin; M A Jay; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

6.  Total cellular fatty acid composition of cultured Pneumocystis carinii.

Authors:  J R Paulsrud; S F Queener; M S Bartlett; J W Smith
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

7.  An enzyme-linked immunosorbent assay for enumeration of Pneumocystis carinii in vitro and in vivo.

Authors:  M M Durkin; M S Bartlett; S F Queener; M M Shaw; C H Lee; J W Smith
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

8.  Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii.

Authors:  M S Bartlett; T D Edlind; M M Durkin; M M Shaw; S F Queener; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 9.  Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.

Authors:  P D Walzer; J Foy; P Steele; M White
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

10.  Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia.

Authors:  P D Walzer; J Foy; P Steele; C K Kim; M White; R S Klein; B A Otter; C Allegra
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.